Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (mice)
PubMed 32426485 · doi:10.1126/sciadv.aaz7492
What was done
Researchers administered adeno-associated virus 9 (AAV9) encoding follistatin (FST) to mice with high-fat diet-induced obesity and post-traumatic knee injury to examine its effects on muscle formation, metabolic inflammation, and joint degeneration.
What was found
The abstract does not provide specific numerical values. It reports that AAV9-mediated FST delivery decreased obesity-induced inflammatory adipokines and cytokines systemically and within joint synovial fluid, and protected mice from post-traumatic osteoarthritis and injury-induced bone remodeling regardless of diet.
Why it matters
Targeting muscle building and anti-inflammatory pathways simultaneously via follistatin gene therapy may offer a disease-modifying strategy for obesity-related and injury-induced osteoarthritis.
Limits
The study was conducted in a mouse model, and findings may not directly translate to human physiology or clinical osteoarthritis. Specific sample sizes, treatment dosages, follow-up durations, and quantitative effect sizes are not reported in the abstract.
Cited by
- supports Follistatin gene therapy expressed locally produces follistatin protein that enters the bloodstream to block myostatin and lower inflammatory markers.